Identification and characterization of an unexpected isomerization motif in CDRH2 that affects antibody activity

References

• Aires da Silva F, Corte-Real S, Goncalves J. Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs. BioDrugs. 2008;22(5):301–10. PMID: 18778112. doi:10.2165/00063030-200822050-00003.
   PubMed Web of Science ®Google Scholar
• Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol. 2005 Sep;23(9):1073–78. PMID: 16151394. doi:10.1038/nbt0905-1073.
   PubMed Web of Science ®Google Scholar
• Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009 May;157(2):220–33. PMID: 19459844; PMCID: PMC2697811. doi:10.1111/j.1476-5381.2009.00190.x.
   PubMed Web of Science ®Google Scholar
• Spanov B, Aboagye V, Olaleye O, Govorukhina N, van de Merbel NC, Bischoff R, van de Merbel NC. Effect of Trastuzumab–HER2 complex formation on Stress-Induced modifications in the CDRs of trastuzumab. Front Chem. 2022 Jan 3;9:794247. PMID: 35047480; PMCID: PMC8762049. doi:10.3389/fchem.2021.794247.
   PubMed Web of Science ®Google Scholar
• Cacia J, Keck R, Presta LG, Frenz J. Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity. Biochemistry. 1996 Feb 13;35(6):1897–903. 10.1021/bi951526c. PMID: 8639672.
   PubMed Web of Science ®Google Scholar
• Vlasak J, Bussat MC, Wang S, Wagner-Rousset E, Schaefer M, Klinguer-Hamour C, Kirchmeier M, Corvaïa N, Ionescu R, Beck A. Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal Biochem. 2009 Sep 15;392(2):145–54. doi: 10.1016/j.ab.2009.05.043. Epub 2009 Jun 2. PMID: 19497295.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yip H, Katta V. Identification of isomerization and racemization of aspartate in the Asp-Asp motifs of a therapeutic protein. Anal Biochem. 2011 Mar 15;410(2):234–43. doi: 10.1016/j.ab.2010.11.040. Epub 2010 Dec 2. PMID: 21130067.
   PubMed Web of Science ®Google Scholar
• Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem. 1987 Jan 15;262(2):785–94. 10.1016/S0021-9258(19)75855-4. PMID: 3805008.
   PubMed Web of Science ®Google Scholar
• Oliyai C, Borchardt RT. Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide. Pharm Res. 1993 Jan;10(1):95–102. PMID: 8430066. doi:10.1023/a:1018981231468.
   PubMed Web of Science ®Google Scholar
• Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl. 2001 Mar 10;752(2):233–45. doi: 10.1016/s0378-4347(00)00548-x. PMID: 11270864.
   PubMedGoogle Scholar
• Doyle HA, Zhou J, Wolff MJ, Harvey BP, Roman RM, Gee RJ, Koski RA, Mamula MJ. Isoaspartyl post-translational modification triggers anti-tumor T and B lymphocyte immunity. J Biol Chem. 2006 Oct 27;281(43):32676–83. doi: 10.1074/jbc.M604847200. Epub 2006 Sep 1. PMID: 16950786.
   PubMed Web of Science ®Google Scholar
• Yang ML, Doyle HA, Gee RJ, Lowenson JD, Clarke S, Lawson BR, Aswad DW, Mamula MJ. Intracellular protein modification associated with altered T cell functions in autoimmunity. J Immunol. 2006 Oct 1;177(7):4541–49. Erratum in: J Immunol. 2006 Dec 15;177(12):8878. PMID: 16982891. doi:10.4049/jimmunol.177.7.4541.
   PubMed Web of Science ®Google Scholar
• Chu GC, Chelius D, Xiao G, Khor HK, Coulibaly S, Bondarenko PV. Accumulation of succinimide in a recombinant monoclonal antibody in mildly acidic buffers under elevated temperatures. Pharm Res. 2007 Jun;24(6):1145–56. Epub 2007 Mar 24. PMID: 17385019. doi:10.1007/s11095-007-9241-4.
   PubMed Web of Science ®Google Scholar
• Ouellette D, Chumsae C, Clabbers A, Radziejewski C, Correia I. Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule. MAbs. 2013 May-Jun;5(3):432–44. Epub 2013 Apr 22. PMID: 23608772; PMCID: PMC4169036. doi:10.4161/mabs.24458.
   PubMed Web of Science ®Google Scholar
• Radkiewicz JL, Zipse H, Clarke S, Houk KN. Neighboring side chain effects on asparaginyl and aspartyl degradation: an ab initio study of the relationship between peptide conformation and backbone NH acidity. J Am Chem Soc. 2001 Apr 18;123(15):3499–506. doi: 10.1021/ja0026814. PMID: 11472122.
   PubMed Web of Science ®Google Scholar
• Yan B, Steen S, Hambly D, Valliere-Douglass J, Vanden Bos T, Smallwood S, Yates Z, Arroll T, Han Y, Gadgil H, et al. Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. J Pharm Sci. 2009 Oct; 98 (10): 3509–21. 10.1002/jps.21655: PMID: 19475547
   PubMed Web of Science ®Google Scholar
• Yu XC, Joe K, Zhang Y, Adriano A, Wang Y, Gazzano-Santoro H, Keck RG, Deperalta G, Ling V. Accurate determination of succinimide degradation products using high fidelity trypsin digestion peptide map analysis. Anal Chem. 2011 Aug 1;83(15):5912–19. doi: 10.1021/ac200750u. Epub 2011 Jul 1. PMID: 21692515.
   PubMed Web of Science ®Google Scholar
• Sydow JF, Lipsmeier F, Larraillet V, Hilger M, Mautz B, Mølhøj M, Kuentzer J, Klostermann S, Schoch J, Voelger HR, et al.Kettenberger H. Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regionsPLos One2014 Jun 2496e10073610.1371/journal.pone.0100736 PMID: 24959685; PMCID: PMC4069079
   PubMed Web of Science ®Google Scholar
• Wakankar AA, Borchardt RT, Eigenbrot C, Shia S, Wang YJ, Shire SJ, Liu JL. Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies. Biochemistry. 2007 Feb 13;46(6):1534–44. 10.1021/bi061500t. Epub 2007 Jan 17. PMID: 17279618.
   PubMed Web of Science ®Google Scholar
• Irudayanathan FJ, Zarzar J, Lin J, Izadi S. Deciphering deamidation and isomerization in therapeutic proteins: effect of neighboring residue. MAbs. 2022 Jan-Dec;14(1):2143006. PMID: 36377085; PMCID: PMC9673968. doi:10.1080/19420862.2022.2143006.
   PubMed Web of Science ®Google Scholar
• Lu X, Nobrega RP, Lynaugh H, Jain T, Barlow K, Boland T, Sivasubramanian A, Vásquez M, Xu Y. Deamidation and isomerization liability analysis of 131 clinical-stage antibodies. MAbs. 2019 Jan;11(1):45–57. Epub 2018 Dec 10. PMID: 30526254; PMCID: PMC6343770. doi:10.1080/19420862.2018.1548233.
   PubMed Web of Science ®Google Scholar
• Clarke S. Propensity for spontaneous succinimide formation from aspartyl and asparaginyl residues in cellular proteins. Int J Pept Protein Res. 1987 Dec;30(6):808–21. PMID: 3440704. doi:10.1111/j.1399-3011.1987.tb03390.x.
   PubMedGoogle Scholar
• Doyle HA, Gee RJ, Mamula MJ. Altered immunogenicity of isoaspartate containing proteins. Autoimmunity. 2007 Mar;40(2):131–37. PMID: 17453712. doi:10.1080/08916930601165180.
   PubMed Web of Science ®Google Scholar
• Hambly DM, Banks DD, Scavezze JL, Siska CC, Gadgil HS. Detection and quantitation of IgG 1 hinge aspartate isomerization: a rapid degradation in stressed stability studies. Anal Chem. 2009 Sep 1;81(17):7454–59. doi: 10.1021/ac901258g. PMID: 19630420.
   PubMed Web of Science ®Google Scholar
• Xiao G, Bondarenko PV. Identification and quantification of degradations in the Asp-Asp motifs of a recombinant monoclonal antibody. J Pharm Biomed Anal. 2008 May 12;47(1):23–30. doi: 10.1016/j.jpba.2007.11.050. Epub 2007 Dec 14. PMID: 18201853.
   PubMed Web of Science ®Google Scholar
• Sreedhara A, Cordoba A, Zhu Q, Kwong J, Liu J. Characterization of the isomerization products of aspartate residues at two different sites in a monoclonal antibody. Pharm Res. 2012 Jan;29(1):187–97. Epub 2011 Aug 2. PMID: 21809161. doi:10.1007/s11095-011-0534-2.
   PubMed Web of Science ®Google Scholar
• Xie M, Aubé J, Borchardt RT, Morton M, Topp EM, Vander Velde D, Schowen RL. Reactivity toward deamidation of asparagine residues in beta-turn structures. J Pept Res. 2000 Sep;56(3):165–71. PMID: 11007273. doi:10.1034/j.1399-3011.2000.00764.x.
   PubMedGoogle Scholar
• Spiekermann K, Hiddemann W. Molekulare Zielstrukturen in der Onkologie [Molecular target structures in oncology]. Internist (Berl). 2005 Aug;46(8):856–60. German PMID: 16007411. doi:10.1007/s00108-005-1463-0.
   Google Scholar
• Robinson NE, Robinson AB. Molecular clocks. Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):944–49. doi: 10.1073/pnas.98.3.944. PMID: 11158575; PMCID: PMC14689.
   PubMed Web of Science ®Google Scholar
• Robinson NE. Protein deamidation. Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5283–88. doi: 10.1073/pnas.082102799. PMID: 11959979; PMCID: PMC122761.
   PubMed Web of Science ®Google Scholar
• Capasso S, Balboni G, Di Cerbo P. Effect of lysine residues on the deamidation reaction of asparagine side chains. Biopolymers. 2000 Feb;53(2):213–19. PMID: 10679625. 10.1002/(SICI)1097-0282(200002)53:2<213:AID-BIP11>3.0.CO;2-C.
   PubMed Web of Science ®Google Scholar
• Liu YD, van Enk JZ, Flynn GC, van Enk JZ. Human antibody Fc deamidation in vivo. Biologicals. 2009 Oct;37(5):313–22. Epub 2009 Jul 15. PMID: 19608432. doi:10.1016/j.biologicals.2009.06.001.
   PubMed Web of Science ®Google Scholar
• Mehl JT, Sleczka BG, Ciccimaro EF, Kozhich AT, Gilbertson DG, Vuppugalla R, Huang CS, Stevens B, Mo J, Deyanova EG, Wang Y, et al. Quantification of in vivo site-specific Asp isomerization and Asn deamidation of mAbs in animal serum using IP-LC–MS. Bioanalysis. 2016 Aug;8(15):1611–22. doi: 10.4155/bio-2016-0035. Epub 2016 Jul 11. PMID: 27397670.
   PubMed Web of Science ®Google Scholar